- Report
- May 2024
- 137 Pages
Global
From €3585EUR$3,999USD£3,094GBP
- Report
- May 2024
- 138 Pages
Global
From €3585EUR$3,999USD£3,094GBP
- Report
- May 2024
- 133 Pages
Global
From €3585EUR$3,999USD£3,094GBP
- Report
- May 2024
- 129 Pages
Global
From €3585EUR$3,999USD£3,094GBP
- Report
- July 2024
- 110 Pages
Global
From €4258EUR$4,750USD£3,675GBP
- Report
- February 2024
- 120 Pages
Global
From €4258EUR$4,750USD£3,675GBP
- Report
- April 2023
- 130 Pages
Global
From €4258EUR$4,750USD£3,675GBP
- Report
- April 2023
- 119 Pages
Global
From €4258EUR$4,750USD£3,675GBP
- Report
- April 2023
- 110 Pages
Global
From €4258EUR$4,750USD£3,675GBP
- Report
- August 2022
- 120 Pages
Global
From €4258EUR$4,750USD£3,675GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1793EUR$2,000USD£1,547GBP
- Report
- June 2024
- 406 Pages
Global
From €4478EUR$4,995USD£3,864GBP
- Report
- January 2024
- 206 Pages
Global
€4478EUR$4,995USD£3,864GBP
- Report
- January 2024
- 168 Pages
Global
€4478EUR$4,995USD£3,864GBP
- Report
- May 2026
- 193 Pages
Canada
From €4348EUR$4,850USD£3,752GBP
- Report
- May 2026
- 200 Pages
Mexico
From €4348EUR$4,850USD£3,752GBP
- Report
- March 2025
- 150 Pages
Global
From €4348EUR$4,850USD£3,752GBP
- Report
- May 2026
- 151 Pages
Australia
From €4348EUR$4,850USD£3,752GBP
- Report
- May 2026
- 152 Pages
Brazil
From €4348EUR$4,850USD£3,752GBP
- Report
- May 2026
- 153 Pages
Canada
From €4348EUR$4,850USD£3,752GBP

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease.
Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs.
Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more